jm1c00932_si_001.pdb (2.69 MB)
Download fileDiscovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase‑1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation
dataset
posted on 21.10.2021, 08:33 authored by Lufeng Zheng, Ren Ren, Xiaolian Sun, Yunting Zou, Yiru Shi, Bin Di, Miao-Miao NiuDual inhibition of tubulin and poly(ADP-ribose)
polymerase-1 (PARP-1)
may become an attractive approach for cancer therapy. Here, we discover
a dual tubulin/PARP-1 inhibitor (termed as TP-3) using structure-based
virtual screening. TP-3 shows strong dual inhibitory effects on both
tubulin and PARP-1. Cellular assays reveal that TP-3 shows superior
antiproliferative activities against human cancer cells, including
breast, liver, ovarian, and cervical cancers. Further studies indicate
that TP-3 plays an antitumor role through multiple mechanisms, including
the disturbance of the microtubule network and the PARP-1 DNA repairing
function, accumulation of DNA double-strand breaks, inhibition of
the tube formation, and induction of G2/M cell cycle arrest and apoptosis.
In vivo assessment indicates that TP-3 inhibits the growth of MDA-MB-231
xenograft tumors in nude mouse with no notable side effects. These
data demonstrate that TP-3 is a dual-targeting, high-efficacy, and
low-toxic antitumor agent.
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
vivo assessment indicatesnotable side effectscellular assays revealcell cycle arrestbased pharmacophore modeling231 xenograft tumorstoxic antitumor agenthuman cancer cellsbased virtual screeningpoly ( adpvirtual screeningcancer therapyantitumor roletube formationstudies indicatestrand breaksnude mousemultiple mechanismsmolecular dockingmicrotubule networkmay becomedna doubledata demonstratecervical cancersattractive approach